ALX Oncology shares are trading higher after the company released interim Phase 2 data from its ASPEN-06 trial of evorpacept in advanced HER2-positive gastric cancer.
Portfolio Pulse from Benzinga Newsdesk
ALX Oncology has released interim Phase 2 data from its ASPEN-06 trial of evorpacept in advanced HER2-positive gastric cancer, which has led to a rise in the company's stock.
October 03, 2023 | 10:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ALX Oncology's stock is trading higher following the release of positive interim Phase 2 data from its ASPEN-06 trial.
The release of positive interim Phase 2 data from ALX Oncology's ASPEN-06 trial has led to a rise in the company's stock. This is because positive trial results often lead to increased investor confidence, which can drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100